The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
The German Federal Joint Committee (G-BA) plans to decide on reimbursement of breast cancer biomarker tests in Q4.
The researchers designed a transcriptome sequencing assay that identifies clinically relevant gene fusions in 541 genes.
In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.
The company hopes to replicate its early data in future studies, making a case that better early diagnosis can improve outcomes for patients with schizophrenia and bipolar disorder.
The company's total revenues were $23.1 million, supported by growth across the firm's instrument and consumables sales, and its research collaboration business.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
As part of the approval, DermTech will market and sell the pigmented lesions assay in Canada, while samples will be processed at the company's lab in California.
UCSF researchers will use NantHealth's GPS Cancer molecular analysis test in their molecular profiling study of metastatic breast cancer.